LivaNova PLC
No SEC Form 4 filings for $LIVN in the last 30 days.
See all $LIVN insider activity →LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.
LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.
LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.
Over the past 7 days, alphai's AI scored 5 news stories mentioning LIVN (LivaNova PLC). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent LIVN coverage spans earnings, financial news and technology.
Guidance raise with offsetting free-cash-flow cut and a next-generation OSA PMA submission delay creates a mixed near-term setup for earnings multiple and forward cash-flow expectations.
Guidance raises and margin/FCF detail suggest improving fundamentals, but higher capex and lower FCF guidance temper near-term cash-flow upside.
Guidance raise plus a long-term Thermo Fisher oxygenator-component supply agreement should support near-term sentiment and reduce supply risk.
The earnings beat plus a second straight annual guidance raise is a direct fundamental catalyst supporting near-term upside momentum.
Guidance raise plus a new oxygenator component supply agreement and favorable Italian tax ruling are near-term positive catalysts for LIVN’s earnings power and risk profile.
alphai scores every news story that mentions LIVN with an AI model for sentiment and relevance, and aggregates insider trades from LivaNova PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.
7 min readLivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.
6 min readLivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.
7 min readLivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.
3 min readLivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev
6 min readLivaNova (Nasdaq: LIVN) reported new OSPREY study data at SLEEP 2026 showing its PolySync programming increased the cumulative apnea-hypopnea index (AHI) responder rate to 84.5% in moderate-to-severe obstructive sleep apnea patients treated with proximal hypoglossal nerve stimulation. The company said PolySync reprogramming converted most initial non-responders and improved AHI and oxygen desaturation index, with no serious treatment-emergent adverse events.
4 min readLivaNova PLC (LIVN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. livn-20260610 0001639691 false 0001639691 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readBianchi Francesco sold 1,800 shares of LivaNova PLC (LIVN) at $75.75 ($0.14M total) on 2026-05-26.
1 min readLivaNova PLC announced that Stefano Folli will join the company as President of its Cardiopulmonary business unit, effective June 1. He will succeed Franco Poletti, who is retiring on July 31, with a transition period expected over several months. Folli, who previously held leadership roles at Philips, will oversee the strategic growth of the nearly $800 million business.
2 min readTudor Investment Corp ET AL recently acquired a new stake of 33,332 shares in LivaNova PLC (LIVN) during the third quarter, valued at approximately $1.75 million. Institutional ownership of LivaNova is high at 97.64%, with other firms like Parkman Healthcare Partners LLC also significantly increasing their holdings. LivaNova reported strong Q3 earnings, beating analyst estimates, and provided positive FY2026 guidance, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $74.78.
2 min read
